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Abstract
Malignant melanoma is an aggressive disease. The anorectal region is the most 
common site of primary gastrointestinal malignant melanoma. Due to its low 
incidence, the diagnosis is often delayed. The most characteristic clinical feature of 
this tumor is its brown-black appearance due to the melanin pigment. However, the 
pigmentation may be absent in up to 20% cases. Timely diagnosis and treatment are 
crucial for achieving good long-term outcomes. Surgical excision remains the treat-
ment of choice for localized disease. However, the extent of surgery has been a mat-
ter of debate. Anorectal melanoma is a highly malignant disease, and more than 50% 
cases have metastasis at the time of diagnosis. Targeted therapies especially immune 
check point inhibitors have brought about a paradigm shift in the management of 
cutaneous melanoma. They are being increasingly used for mucosal melanomas, and 
their role in anorectal melanoma is being investigated in various clinical trials.
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1. Introduction
Anorectal melanoma (AM) is a rare type of anorectal malignancy. It accounts 
for about 1% of all anal cancers [1]. Due to its rarity, it is often misdiagnosed as 
hemorrhoids, rectal adenocarcinoma and polyps. Its early diagnosis and treat-
ment are important to improve the prognosis as it is an aggressive disease with 
high malignant potential. There are no standard guidelines for the diagnosis, stag-
ing and treatment of AM. In this chapter, we have discussed the epidemiological, 
pathogenesis, clinical manifestations, treatment and prognosis of AM.
2. Epidemiology
Mucosal melanoma (MM) accounts for 1–2% of all melanomas with incidence 
of 2–2.6 cases per million people/year [2]. The most common sites of MM are 
head and neck followed by anorectal region [3]. AM is the most common type of 
gastrointestinal melanoma and the third most common type of melanoma [3]. AM 
accounts for 16.5% cases of mucosal melanomas [4]. The annual incidence rate of 
AM is 0.259 in males and 0.407 in females according to Surveillance, Epidemiology, 
and End Results (SEER) analysis and, the incidence has been steadily increasing 
over the years [5, 6]. However, the exact reasons for rising incidence are poorly 
understood. The prevalence of AM is 1.6 to 2.3 times higher in females than males 
and two times higher in Caucasians than African Americans [7, 8].
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3. Pathogenesis and genetics
Melanocytes are derived from the neural crest cells. They migrate to the cutis and 
mucocutaneous junctions during the embryonal life. The chief function of melano-
cytes is their antioxidant activity, which helps to counteract the free radicals gener-
ated by the ultraviolet rays. Additionally, they contribute to the regional immune 
response [9, 10]. It has been postulated that the malignant transformation of mela-
nocytes occurs due to oxidative stress and/or immunosuppression [9]. Other theories 
on AM suggest that they may be derived from Schwann cells of autonomic nervous 
system or the cells of the amine-precursor uptake and decarboxylation (APUD) 
system of the gastrointestinal tract [11]. Ultraviolet rays play a central role in the 
development of cutaneous melanoma (CM) unlike mucosal melanoma (MM). Hence, 
other pathways are involved in the development of MM which are poorly understood.
MM have different mutation profile compared to cutaneous melanomas [12]. 
BRAF mutations are infrequent, with an increased rate of c-KIT overexpression [13]. 
The incidence of BRAF, NRAS and c-KIT mutations are 5–16%, 14–18% and 11–15% 
respectively [14–16]. The mutation profiles of mucosal melanomas indicate that they 
have potential sensitivity to CDK4/6 and MEK inhibitors [16]. A study by Newell et al. 
have identified various mutational signatures in mucosal melanomas [16]. They found 
that mutations for melanoma in facial sites are different from that found in lower 
body sites. For example, SF3B1 hotspot mutations are common in AM and vulvovagi-
nal melanomas, unlike other sites. Another study by Donizy et al. found that high poly 
(ADP-ribose) polymerase 1 (PARP-1) expression alone and along with high indole-
amine 2,3-dioxygenase 1 (IDO-1) expression in mucosal melanomas was associated 
with worse overall and disease-specific survival [17]. Some studies have speculated 
that some viruses such as human papilloma virus (HPV) and human herpes virus 
(HHV-8) could be involved in the development of primary MM [11]. However, HPV 
DNA and HHV-8 DNA could not be detected in cases with AM [18, 19].
4. Clinical features
4.1 Clinical signs and symptoms
The clinical features of AM mimic that of benign anorectal disorders leading 
to delay in diagnosis. The main clinical symptoms include bleeding per rectum, 
perianal pain, pruritus ani, tenesmus, perianal mass, inguinal mass (Figure 1). 
It is more frequent in females than males (1.7:1). It is most frequently observed in 
6th and 7th decade of life [5]. The most important aspect of clinical diagnosis is a 
careful perianal and per-rectal examination. AM appears as an ulcerated or nodular 
lesion with an irregular surface showing brown or black pigmentation (Figure 1). 
Moreover, these are vascular lesions which bleed on touching. Frequently, in about 
20% cases, the pigmentation may be absent. In small lesions, a high index of sus-
picion is required for timely diagnosis due its appearance similar to hemorrhoids. 
Hence, whenever in doubt, incisional or excisional biopsy should be performed for 
histopathological examination to diagnose AM. Another important clinical find-
ing in cases of AM is the presence of inguinal lymphadenopathy. Inguinal lymph 
nodal metastases are usually seen in cases of anal melanoma. In cases with inguinal 
lymphadenopathy, fine needle aspiration and cytological examination for the 
enlarged lymph nodes can help in making the diagnosis.
Serum markers can aid in the diagnosis of AM. However, they are elevated in 
advanced cases of melanoma and often used as an adjunct to the other investiga-
tions for diagnosis. Lactate dehydrogenase (LDH) is a commonly used marker 
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for the detection of distant metastases in patients with melanoma [20]. Other 
markers include S-100B, melanoma inhibitor activity (MIA) protein, enolase and 
YKL-40 [21–24]. Elevated levels of these markers have been associated with a 
poor prognosis.
4.2 Radiological studies
The main role of radiological investigations is to determine the extent of the dis-
ease. Chest radiograph can detect obvious pulmonary metastases while abdominal 
ultrasound can detect liver metastasis [25]. Computed tomography (CT) is helpful 
in accurate staging of the disease (Figure 2). On CT, the liver lesions show late 
arterial enhancement and hypoattenuation of liver parenchyma in the portal venous 
phase [26]. The pulmonary metastases on CT chest appear as multiple end-arterial 
nodules with tree-in-bud appearance [25]. Magnetic resonance imaging (MRI) is a 
good imaging modality for accurate assessment of the local invasion of the tumor 
Figure 1. 
Perianal examination showing the ulcerated mass in a patient with locally advanced anorectal melanoma.
Figure 2. 
Anorectal melanoma appeared as a heterogeneously enhancing polypoidal mass (arrow) on contrast enhanced 
CT (A) and MRI (B, C).
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as well as for the detection of metastatic lesions in the liver (Figure 2) [27]. PETCT 
is the recommended imaging for the staging and response assessment of metastatic 
melanoma [20]. Melanoma cells have higher FDG avidity compared to normal tis-
sues due to high metabolic rate [20].
4.3 Endoscopic studies
For deeply located AM, especially rectal melanoma, endoscopy is very useful to 
visualize the lesions and take biopsies for histological examination. On endoscopy, 
the lesions appear as black or brownish plaques, ulcers or polyps due to the melanin 
pigment. The accuracy of endoscopic biopsy ranges from 50 to 100% [28]. The 
accuracy is low for lesions with atypical endoscopic characteristics. Endoscopic 
ultrasound is helpful in determining the depth of the lesions especially the extent of 
anal sphincter involvement and to look for perirectal lymphadenopathy. The lesions 
appear hypoechoic with uneven internal echoes [28].
5. Histopathology
As none of the clinical features are unique to AM, histological examination of 
the suspected lesions should be performed for the definitive diagnosis of AM. The 
main cytological features of AM are highly cellular smear, presence of binucleated 
or multinucleated cells, and cytoplasmic melanin pigment. However, melanin pig-
ment is found in only about 27% cases [29].
On gross examination, the lesion appears as polypoidal or ulcerated lesion with 
or without brown-black pigmentation (Figure 3). The histological description 
includes cell type, degree of melanin pigmentation and mitotic index (Ki-67) [20]. 
Typically, AM consists of spindle-shaped (Figure 4) or epitheloid cells with high 
nuclear pleomorphism and presence of cytoplasmic melanin granules (Figure 5) 
[30]. About 20% cases are truly amelanotic on histology [31]. Four subtypes of AM 
based on histology are epitheloid, spindle cell, lymphoma-like and pleomorphic 
[32]. In the absence of melanin pigments, the tumor morphology can mimic lym-
phoma and gastrointestinal stromal tumors. Immunohistochemistry helps in dif-
ferentiate AM from other tumors. Melanoma antigens such as S-100, HMB-45 and 
vimentin are positive in 78, 94 and 100% cases (Figure 6) [31]. The characteristic 
Figure 3. 
Gross examination of the specimen after abdominoperineal resection showing the pigmented polypoidal hard 
growth (arrow) of about 3 cm reaching up to the outer surface (A) and involving the anorectal junction (B).
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marker of gastrointestinal stromal tumor, c-Kit is positive in about three-fourth 
cases of AM (Figure 4) [32]. In some cases, the tumor cells may show positivity 
for CEA, CD30 and CD68 similar to colorectal adenocarcinoma and other tumors 
[33]. Hence, a panel of markers should be tested to confirm the diagnosis of AM 
in doubtful cases. Some unique markers for melanoma with high specificity and 
low sensitivity include Melanin A, Mart-1 antibodies [20]. Interestingly, Ki-67 
and proliferating cell nuclear antigen (PCNA) immunostains have been found to 
predict survival in patients with AM [31].
Tumor-infiltrating lymphocytes (TILs) provide a reflection of the tumor 
microenvironment. Presence of TILs in high concentration is associated with high 
programmed cell death protein 1 (PD-1) [34]. High PD-1 expression indicates bet-
ter prognosis for patients with AM due to good response to targeted therapies. TILs 
can be seen on hematoxylin and eosin stains and also with immunohistochemistry. 
The majority of these TILs are CD8-positive cells. In a study of 43 AM patients, TILs 
were present in 55% cases [35].
Figure 4. 
Histological examination of anorectal melanoma showing the diffuse infiltration of the tissue by spindle-
shaped cells with dense eosinophilic cytoplasm and pleomorphic nuclei: (A) H&E x10, (B) H&E x 20, and (C) 
H&E x 40. Immunohistochemical analysis revealed positive staining with c-KIT (D) and Melan A (E).
Figure 5. 
Microscopic examination of the tumor showing diffuse infiltration of the anorectal region by large epitheloid 
cells with vesicular and prominent nuclei (A) H&E x 10 and (B) H&E x 40.
Figure 6. 
Immunohistochemical analysis of the anorectal melanoma showing positivity for HMB 45 (A), Melan A (B) 
and SOX 10 (C).
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Figure 7. 
A suggested algorithm for the management of anorectal melanoma. (WLE—Wide local excision,  
APR—Abdominoperineal resection, systemic therapy—Chemotherapy, targeted therapies).
6. Diagnosis and staging
As CM and MM are known for early hematogenous spread, secondary gastro-
intestinal melanomas are not rare. Hence, for differentiation between primary and 
secondary melanoma, the following criteria must be satisfied: absence of melanoma 
at any other cutaneous or mucosal sites confirmed by thorough clinical including 
genital, oropharyngeal, ophthalmological and endoscopic examination; no past 
history of melanoma and presence of atypical melanocytes in the basal epithelium 
of the tissue sample [36].
There is no formal staging system for AM. However, the most commonly 
described system for AM in previous studies is the Ballantye clinical system which 
has three stages as follows: Stage I – localized disease, Stage II – presence of inguinal 
or pelvic lymph nodes and stage III – distant metastasis [37–39]. Interestingly, a 
recent study by Nagarajan et al. involving 160 AM patients found that the clinical 
American Joint Cancer Committee (AJCC) staging system (8th edition) for CM sig-
nificantly stratified disease-specific survival of AM patients. Moreover, the authors 
recommended slight modifications in the AJCC ‘T’ category criteria of staging for 
better stratification [40]. Hence, either of the two staging systems can be used to 
prognosticate the disease in patients with AM.
7. Treatment
The main treatment options for AM are surgery, chemotherapy, radiation therapy 
and targeted therapies. According to a study which analyzed data of 1333 AM patients 
from National Cancer Database from 2004 to 2015, the authors found that surgery 
alone (48.7%) was the most common treatment given to the AM patients [6]. The use 
of chemotherapy and radiotherapy was similar throughout the study period but there 
has been a rapid increase in the use of targeted therapies for AM in the last few years. 
In Figure 7, we have provided an overview of the management of patients with AM.
7.1 Surgery
Surgery remains the mainstay of treatment. Most of the previous studies recom-
mend surgical excision for Stage I and II AM. However, the benefit of lymph node 
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dissection in AM has not been established. Unlike rectal adenocarcinoma and CM, 
lymph nodal metastasis has no significant impact on the long-term survival [41, 42]. 
The systemic dissemination of the disease occurs early in the course of the disease 
even before lymph nodal metastasis [43]. The 2020 UK National guidelines recom-
mend R0 surgical resection in the least radical fashion [44]. Lymphadenectomy 
should be performed in cases with metastatic regional lymph nodes.
The main procedures for AM include: (1) function-preserving procedures such 
as endoscopic mucosal resection (EMR), wide local excision (WLE); (2) radical 
procedures such as low anterior resection (LR), abdominoperineal resection (APR). 
In a meta-analysis of 31 studies [43], 7 studies found APR to be superior to WLE 
[45–47], 11 studies found WLE to be better than APR [41, 48, 49] while 10 stud-
ies reported similar survival outcomes between the two procedures [42, 50, 51]. 
However, the local recurrence rate was significantly higher in WLE group (57% 
vs. 21.6%). The most recent study of 305 AM patients treated from 2004 to 2015 
found no difference in overall survival (OS) between local and transabdominal 
resection (2.54 vs. 1.86 years, p = 0.77) [52]. Another recent meta-analysis found no 
significant difference in OS, disease-free survival (DFS) and local recurrence rates 
between WLE and APR on analyzing of data from 23, 7 and 19 studies, respectively 
[53]. So, we believe that WLE with regular surveillance should be the preferred 
approach. If WLE is not feasible or there is local recurrence without distant metas-
tasis, then APR should be considered [39].
7.2 Chemotherapy
There is no standard chemotherapy regimen for AM due to the rarity of the 
disease. However, dacarbazine in combination with high-dose interferon and inter-
leukin-2 was found to be effective in 10–20% cases of mucosal melanomas [54]. In 
a Turkish study of 6 AM patients, all patients received APR followed by adjuvant 
chemo- and radiotherapy [55]. The adjuvant chemotherapy included dacarbazine 
and temozolomide. In addition, two patients received ipilimumab, and one patient 
received interferon therapy. At the mean postoperative follow up of 12.5 months 
(6–26 months), 4 patients died due to extensive distant metastases while two 
patients were disease free [55]. In another study of 22 patients with metastatic AM, 
six patients received dacarbazine while one patient received temozolomide and 
thalidomide. The median survival in these patients was 9 months [56].
7.3 Radiation therapy
Radiation therapy has been used for palliation or in the adjuvant setting after 
organ preserving surgery such as wide local excision to reduce the chances of local 
recurrence. A study by Kelly et al. of 54 patients treated by WLE followed by hypo-
fractionated radiotherapy reported good local control in 82% cases but the 5-year 
OS was only 30% [57].
7.4 Targeted therapies
Immune checkpoint inhibitors have become the standard of care in the treat-
ment of metastatic CM. However, their role in MM is still under investigation. 
Cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed-death 
(PD1) protein are the most common immune checkpoint targets expressed on 
activated T-cells with immunosuppressive effects. Ipilimumab is a fully human 
monoclonal that blocks the binding of CTLA4 with CD80 and CD86 ligands. It was 
the first agent approved for the treatment of advanced melanoma. It has an indirect 
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effect on the T-cell mediated antitumor immune response. It prolongs survival in 
about 20% patients [58].
The ligands of PD1, PDL1 (B7H8) and PDL2 (B7DC) are expressed on tumor 
cells and other cell types. The immunosuppression of PD1 receptor is due to the 
interaction between T lymphocytes and tumor cells. PD1 blockage seems to be 
more effective toward t-cell activation than CTLA-4 inhibition. Nivolumab and 
pembrolizumab are humanized monoclonal antibodies against PD1. In a study 
of 44 MM patients having metastasis including 14 patients with AM, pembro-
lizumab was found to be more effective than ipilimumab in prolonging the PFS 
[59]. Another study reported the objective response rate of 23% and 37% in MM 
patients receiving nivolumab alone and in combination with ipilimumab respec-
tively [60]. A study of eight patients treated by immunotherapy, one patient on 
PD-1 based combination therapy had stable disease and one patient with PD-1 
monotherapy had complete response while rest of the six patients had progressive 
disease [35].
Mitogen-activated protein kinase (MAPK) pathway plays an important role in 
the cell survival, multiplication and differentiation. Overactivation of this pathway 
has been detected in various human cancers. Through this pathway many enzymatic 
kinases are expressed that are part of phosphorylation cascade including RAS, RAK, 
MEK and ERK kinases [61]. Overactivation of BRAF is one of the most common 
cause of abnormal MAPK signaling seen in cancers [62]. The MAPK pathway is 
activated in 40–50% cases of metastatic melanomas [63]. Hence, various BRAF and 
MEK inhibitors have been used for the treatment of metastatic melanoma.
Dabrafenib is a competitive reversible ATP inhibitor with selective BRAF inhibi-
tion. It has been found to be effective in 50–70% cases of melanomas with BRAF 
V600E or V600K mutations [64, 65]. Additionally, use of MEK inhibitors in com-
bination with BRAF inhibitors such as vemurafenib plus cobimetinib or dabrafenib 
plus trametinib have prolonged PFS and OS of melanoma patients.
KIT kinase inhibitors such as sorafenib, imatinib, dasatinib, have been found to 
be very useful in the treatment of gastrointestinal stromal tumors. But they have 
not been very successful in the treatment of melanomas. However, some studies 
on KIT-mutated metastatic MM have shown good response to these KIT kinase 
inhibitors [66–69].
NRAS mutations are present in 15–20% cases of melanoma [70]. Tumors with 
NRAS mutations have aggressive tumor biology and show poor response to immune 
check point inhibitors [70]. MEK inhibitors especially binimetinib has shown 
promising results in phase II/III studies [71]. Several phase I/II trials testing the role 
of MEK inhibitors in combination with PI3K/AKT inhibitors are underway mainly 
including metastatic CM patients [70].
In summary, patients with AM, unlike CM, have poor response to targeted 
therapies. Also, the type of targeted therapy to be used depends upon the muta-
tion analysis of the tumor as highlighted in Figure 8. However, the response rates 
with targeted therapies are better than conventional chemotherapy and are being 
increasingly used in clinical trials and oncology practice. Some immune checkpoints 
inhibitors and BRAF inhibitors are being used as adjuvant therapies in the ongoing 
clinical trials to reduce the recurrence rate after complete surgical excision.
7.5  Other therapies such as immune mediators such as interferon-a, 
interleukin-2
Studies have found alfa-interferon to improve relapse-free survival and overall 
survival in patients with CM. In CM, particularly in patients with positive nodal 
involvement, α-interferon at the dose of 20 MU/m2/day intravenously 5 day weekly 
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for 4 weeks, followed by 10 MU/m2/day subcutaneously three times weekly for 
4–8 weeks had demonstrated a significant prolongation of DFS and OS [72]. 
However, their role in AM is not clear.
8. Prognostic factors
The 5-year survival rate of colorectal melanoma ranges from 4.3% to 17.4% [73]. 
The median survival of AM has been reported as 21 months [95% CI: 11–30] [15]. The 
5-year OS rates of Stage I, II and III are 26.7%, 9.8% and 0% respectively [35].
A recent study by Menon et al. of 209 nonmetastatic AM patients found no 
significant difference in the median overall survival with chemotherapy (1.41 vs., 
2.24 years, p = 0.16), radiotherapy (2.55 vs. 1.96 years, p = 0.31) and targeted therapy 
(2.07 vs. 1.96 years, p = 0.95) [52]. This study also found no benefit of adjuvant 
therapy in nonmetastatic AM cases after surgery. On the other hand, in 116 patients 
with metastatic disease, targeted therapy showed a trend toward higher survival (1.33 
vs. 0.55 years, p = 0.06). On multivariate analysis, younger age, urban location of the 
patients and surgery were associated with better OS [52]. Other studies have found 
that age, tumor thickness, presence of ulceration, lymphovascular invasion, perineu-
ral invasion and tumor AJCC stage are the main predictors of survival [15, 39, 40].
The reported 1-,2-,3-,4-OS rates have been 67,40,40 and 32% in APR group and 
100,100,67, and 67% in WLE group [39]. The median survival in WLE and APR 
groups were 36 and 13 months respectively [3]. In another study by Bello et al., no 
significant difference was found between WLE (n = 81) and APR (n = 14) provided 
the resection margins were tumor-free [74].
The site of origin of melanoma affects the prognosis as seen in cutaneous and 
mucosal melanoma. Whether the location of the tumor such as anal, rectal or anorectal 
affects the prognosis is not clear. In a study of 120 AM patients by Bello et al., the 
authors divided the patients in to three groups: anal (tumor below dentate line), ano-
rectal (tumor at or traversing dentate line) and rectal (tumor above the dentate line). 
They found no significant difference in the DFS (23 vs. 28 vs. 27 months, p = 0.887) and 
Figure 8. 
A flow chart outlining the use of various targeted therapies for the patients with anorectal melanoma  
(molecular testing—Mutation testing can be done by immunohistochemistry or next-generation or  
high-throughput sequencing (NSG); BRAF inhibitors—Dabrafenib, vemurafenib, encorafenib; MEK 
inhibitors—Trametinib, cobimetinib, binimetinib (MEK162); KIT inhibitors—Imatinib, sunitinib, nilotinib; 
immune checkpoint inhibitors—Ipilimumab, nivolumab, pembrolizumab).
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OS (22 vs. 28 vs. 27 months, p = 0.696) between the three groups [74]. Additionally, 
they found no survival benefit with adjuvant radiation or systemic therapy.
In the largest study of 60 Asian patients with AM, the authors found 
age > 70 years, tumor size more than 5 cm, tumor thickness more than 10.5 mm, 
lymph nodal metastasis, tumor invasion beyond deep muscular layer to be associ-
ated with poor disease-specific survival on univariate analysis. Among these 
parameters, only age > 70 years and depth of tumor invasion were independent 
predictors of low disease-specific survival [75].
9. Conclusion
AM is an uncommon malignancy of the anorectal region with high malignant 
potential. Early diagnosis and treatment are required to achieve good long-term 
results. Surgical excision remains the mainstay of curative treatment. AM shows 
poor response to radiotherapy and conventional chemotherapy. Targeted therapies, 
in the recent years, have shown promising results. Future studies with the use of a 
combination of chemotherapy, immune check point inhibitors, BRAF inhibitors, 
and MEK inhibitors are required to improve the long-term survival.
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